{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'It is investigator criteria to determine if the patient needs to be treated with another DMT, and in', 'which case the patient will be discontinued from the study.', 'Concomitant use of systemic corticosteroids for the treatment of MS relapse is allowed during the', 'course of the Study. Relapses may be treated with systemic corticosteroids if clinically necessary', 'and as per Investigator judgment in doses appropriate for paediatric population.', 'The use of systemic corticosteroids or adrenocorticotrophic hormone within 2 weeks prior to MRI', 'assessment is not permitted due to potential interference with MRI assessment.', 'It is recommended that patients complete local immunization requirements at least 6 weeks prior', 'to treatment with alemtuzumab. The ability to generate an immune response to any vaccine', 'following alemtuzumab treatment has not been studied.', 'The safety of immunization with live viral vaccines following a course of alemtuzumab treatment', 'has not been formally studied in controlled clinical trials in MS. Live vaccines must not be', 'administered to MS patients who have recently received a course of alemtuzumab. Also, some', 'experts urge caution in using live pathogen vaccinations in people with MS (National MS Society', 'web site).', 'Property of the Sanofi Group - strictly confidential', 'Page 52', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '9', 'ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT', 'The assessments will be performed according to the schedule presented in the Study Flowchart.', 'See Section 1.2 and Section 10 for further details.', '9.1', 'PRIMARY ENDPOINT', '9.1.1 Primary efficacy endpoint', 'The primary endpoint is the number of new or enlarging T2 lesions on brain MRI, during', 'continuation of prior DMT (Period 1) compared to an equal period after the first course of', 'alemtuzumab treatment (Period 2). The primary efficacy endpoint will be assessed by brain MRI.', '9.1.1.1 Brain MRI', 'For primary endpoint assessment, two periods have been defined', 'Period 1: will occur from M-4 up to MO. An MRI will be performed during the screening', 'period and another at Visit 3. Both MRI will be taken while patients are on their prior', 'DMT. The two MRIs will be compared by a central assessor to count the number of new', 'or enlarging T2 lesions. It is important to ensure that these 2 MRI assessments are', 'performed 4 months (=7 days) apart.', 'Period 2: will occur from M4 to M8: The MRI performed at the M4 visit will be the', 'baseline MRI for Period 2. A second MRI will be performed after alemtuzumab first', 'course of treatment at M8. The two MRIs will be compared by a central assessor to count', 'the number of new or enlarging T2 lesions. It is important to ensure that these 2 MRI', 'assessments are performed 4 months (+7 days) apart.', 'It is expected that Periods 1 and 2 will be of the same length 7 days.', '\"Baseline\" MRI will be collected during the screening visit (baseline for Period 1) and the', 'M4 visit (baseline for Period 2). The \"baseline\" lesion volume for the corresponding period will', 'be adjusted in the generalized estimating equation (GEE) model.', 'Screening MRI is expected to be reviewed locally by PI only for study eligibility confirmation.', 'The MRI assessments will also be available to the investigators to assess safety.', 'In addition to primary endpoint MRIs (Screening, D-7, M4, M8) other MRIs will be performed at', 'M12, M24/at EOTP, and then annually in the Safety Monitoring Phase.', 'All brain MRIs will be reviewed and interpreted by one or more MRI experts at an independent,', \"central facility with no access (ie, blinded) to patients' treatment thereby avoiding bias.\", 'An MRI manual explaining the instructions for standard image acquisition requirements, data', 'transfer, archiving and shipping, and outlining the phantom data approval process will be', 'provided to all centers.', 'Property of the Sanofi Group - strictly confidential', 'Page 53', 'VV-CLIN-0254406 5 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'MRI should not be conducted within 2 weeks of steroid administration due to potential', 'interference with MRI assessment.', '9.2', 'SECONDARY ENDPOINTS', 'Secondary endpoints include the efficacy, quality of life and pharmacokinetic/Pharmacodynami', 'endpoints are listed below, and will be assessed as shown in Section 9.2.1 and Section 9.2.2:', 'Efficacy:', 'The number of patients with new or enlarging T2 lesions during continuation of prior', 'DMT (Period 1) compared to an equal period after the first course of alemtuzumab', 'treatment (Period 2).', 'EDSS (descriptive analysis, ie percentages of stable/improved/worsened since the end of', 'Period 1).', 'Annualized relapse rate (ARR) at Year 2.', 'Cognition test scores: Brief Visuospatial Memory Test - Revised (BVMT-R) and Symbol', 'Digit Modality Test (SDMT); administered at least every 6 months over 2 years.', 'Quality of life:', 'Established generic paediatric QoL measures administered every 6 months over 2 years.', 'Pharmacokinetics/Pharmacodynamics:', 'PK serum concentration and PK parameters (Cmax, Tmax, AUC, AUClast, T1/2z) calculated', 'where possible.', 'PD assessment including lymphocyte subsets.', '9.2.1 Secondary efficacy endpoints', '9.2.1.1 Expanded disability status scale', 'Patient disability will be evaluated using the EDSS (Appendix D), which has long been', 'considered the standard for assessing disability in patients with MS (19).', 'The EDSS is an ordinal clinical rating scale which ranges from 0 (normal neurologic examination)', 'to 10 (death due to MS) in half-point increments. Briefly, the assessing neurologist rates', '7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual ratings)', \"in conjunction with observations and information concerning the patient's mobility, gait, and use\", 'of assistive devices to assign an EDSS score.', 'EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory, while EDSS steps 5.0 to', '9.5 are defined by the impairment to ambulation.', 'Property of the Sanofi Group - strictly confidential', 'Page 54', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}